<DOC>
	<DOCNO>NCT02568683</DOCNO>
	<brief_summary>This study evaluate safety entospletinib ( ENTO ) vincristine ( VCR ) participant relapse refractory B-cell Non-Hodgkin Lymphoma ( NHL ) .</brief_summary>
	<brief_title>Safety Efficacy Entospletinib ( ENTO GS-9973 ) Combined With Vincristine ( VCR ) Adult Participants With Relapsed Refractory B-cell Non-Hodgkin Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Key Measurable disease compute tomograph ( CT ) / and/or positronemission tomography CT ( PETCT ) A ) Dose Escalation Stage : Confirmed diagnosis relapse refractory NonHodgkin Lymphoma ( NHL ) treat prior treatment lymphoid malignancy comprise least 1 regimen contain therapeutic antiCD20 antibody ( eg , rituximab , ofatumumab , GA101 ) least 2 prior combination chemotherapy regimen ( autologous stem cell transplant ) , treat 1 prior combination chemotherapy regimen patient without approved secondline therapy option , require treatment opinion treat physician B ) Dose Expansion Cohorts : Expansion Cohort A : Relapsed refractory DLBCL treat prior treatment lymphoid malignancy comprise least 1 regimen contain therapeutic antiCD20 antibody ( eg , rituximab , ofatumumab , GA101 ) least 2 prior combination chemotherapy regimens autologous stem cell transplant , treat 1 prior combination chemotherapy regimen patient without approved secondline therapy option , require treatment opinion treat physician Expansion Cohort B : Diagnosis relapse refractory Bcell NHL ( DLBCL ) treat prior treatment lymphoid malignancy comprise least 1 regimen contain therapeutic antiCD20 antibody ( eg , rituximab , ofatumumab , GA101 ) least 2 prior combination chemotherapy regimens autologous stem cell transplant , treat 1 prior combination chemotherapy regimen patient without approved secondline therapy option , require treatment opinion treat physician Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Karnofsky performance status ≥ 70 Required screen laboratory data ( within 2 week prior administration study drug ) show study protocol . Adequate organ function define screen laboratory inclusion list Left Ventricular Ejection Fraction ( LVEF ) ≥ 45 % confirm ECHO multigated acquisition ( MUGA ) Discontinuation therapy ( include radiotherapy , chemotherapy , tyrosine kinase inhibitor ( TKIs ) , immunotherapy , investigational therapy treatment cancer least 2 week prior initiation study therapy All acute toxic effect prior antitumor therapy resolve Grade ≤ 1 enrollment , exception alopecia ( grade permit ) For female individual childbearing potential , willingness use protocol recommend method contraception For male individual intercourse female childbearing potential , willingness abstain heterosexual intercourse use protocol recommend method contraception In judgment investigator , participation protocol offer acceptable benefittorisk ratio consider current disease status , medical condition , potential benefit risk alternative treatment individual 's NHL Willingness comply schedule visit , drug administration plan , image study , laboratory test , study procedure , study restriction Have ability understand sign write informed consent form , must obtain prior initiation study procedure Key Diagnosis Primary Mediastinal Large Bcell Lymphoma A life threaten illness , medical condition organ system dysfunction , investigator 's opinion , could compromise individual 's safety interfere absorption metabolism ENTO Active symptomatic central nervous system ( CNS ) disease epidural involvement Uncontrolled intercurrent illness include , limited , unstable angina pectoris psychiatric illness/social situation would limit compliance study requirement Current/ongoing Neuropathy ( sensory motor ) Grade &gt; 1 history Grade ≥ 3 neuropathy prior Vincristine chemotherapy exposure ( documentation history adequate exclude ) Contraindication receive vincristine plan protocolspecified chemotherapy Eligible autologous stem cell transplant History myelodysplastic syndrome , allogeneic stem cell solid organ transplantation History prior lymphoid malignancy registrational histology nonlymphoid malignancy except follow : adequately treat local basal cell squamous cell carcinoma skin , cervical carcinoma situ , superficial bladder cancer , asymptomatic prostate cancer without know metastatic disease requirement therapy require hormonal therapy normal prostate specific antigen ≥ 1 year prior start study drug , cancer complete remission without treatment ≥ 5 year prior enrollment Known hypersensitivity intolerance active substance excipients formulation ENTO Evidence uncontrolled systemic bacterial , fungal , viral infection start study drug Ongoing druginduced liver injury , chronic active Hepatitis C Virus ( HCV ) , chronic active Hepatitis B Virus ( HBV ) , HIV , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , extrahepatic obstruction cause cholelithiasis , cirrhosis liver , portal hypertension Current therapy proton pump inhibitor Pregnancy breastfeed Ongoing active pneumonitis Prior treatment spleen tyrosine kinase ( SYK ) inhibitor Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>